Systems biology and combination therapy in the quest for clinical efficacy

By J. Fitzgerald, Birgit Schoeberl, Ulrik B. Nielsen, Peter K. Sorger. Nature Chemical Biology, 2006

582 citations recorded by the source corpus.

Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/985d43eb235db1fec6445013d5d19a09592dc0ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Radiology, Nuclear Medicine and Imaging

Peter K. Sorger

Citations in the corpus

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model (2015, background): “…example, aneffective drugcombination maytarget multiple proteinsor pathways that are aberrantly activated in disease, but not in normal cells, and thus reduces the chances that a cancer will develop drug resistance by activating bypassing pathways, when compared to standard mono-therapies [1 – 3].”
Network target for screening synergistic drug combinations with application to traditional Chinese medicine (2011, background): “The available evidences showed that molecular synergisms can be emerged from different aspects, for example, protein complexes in cell-regulatory systems [42], crosstalk [43-47] and feedback control in the structures of signal pathways [48,49], stimuli-influenced number of molecules (e.”
Structure-based Systems Biology for Analyzing Off-target Binding (2011, background): “The understanding of the drug response at the systems level is particularly important for understanding polypharmacology since there are many reported examples where the therapeutic efficacy is enhanced through synergistic relationships among multiple targets [107–111].”
A community computational challenge to predict the activity of pairs of compounds (2014, background): “…synergy can potentially complement high-throughput synergy screens, but the few that have been published lack rigorous experimental validation or are appropriate only for compounds that modulate well-studied molecular pathways 15 or that are equivalent to previously established combinations 16 .”
Systems biology approaches for advancing the discovery of effective drug combinations (2015, background): “Drugs inhibiting parts of the same linear pathway may act according to Loewe additivity [17].”
Sequential Application of Anti-Cancer Drugs Enhances Cell Death by Re-wiring Apoptotic Signaling Networks (2012, background): “…interplay between signaling networks argues that a more systematic assessment exploring not only dosage, but also the order of drug presentation, scheduling, and dose duration might uncover cross-pathway effects and efficacious interactions that were missed previously (Fitzgerald et al., 2006).”